the integrated drug discovery platform (IDD) with four new projects from Deerfield 550 Discovery and Development (3DC). However, revenue from Generics segment declined 450 2.7% YoY to Rs. 561cr, impacted by advance buying owing to pandemic, supply 350 disruption and delay of approval of certain key products. Margin contracted on higher R&D; expenses EBITDA stood at Rs. 427cr, decline of 11.0% YoY, with margin contracting 490bps YoY to 23.1%, mainly due to higher R&D; expenses and employee cost related to Biosimilars business. Gross R&D; spends increased 18.1% YoY to Rs. 183cr and employee cost as a...